Innogenetics acquires full PCR license from Roche Diagnostics
Innogenetics and Roche Diagnostics announced that they have signed an agreement by which Roche has granted Innogenetics a full, worldwide license for the use of its patented polymerase chain reaction (PCR) technology in the development and commercialization of Innogenetics' molecular diagnostic products.
Under the terms of the agreement, Innogenetics will pay Roche up to US$ 27.5 million over a four-year period, plus royalties. This broad PCR license will replace the current product specific licensing agreement. The agreement will allow Innogenetics to offer its customers the complete set of PCR reagents and processes to carry out PCR-based nucleic amplification for its diagnostic tests, so that its customers will not have to obtain a separate license from Roche Diagnostics for this purpose. The deal will also enable the Belgian biopharmaceutical company to fully integrate PCR technology in its next-generation diagnostic platform as well as in its complete range of molecular diagnostic tests, thereby ensuring optimal quality of test performance.
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
